联邦制药(03933.HK)拟10.3亿元向出售恒大(成都)两幅四川成都商住地快
格隆汇8月9日丨联邦制药(03933.HK)公布，于2019年8月7日，公司全资附属联邦制药(香港)与独立第三方恒大(成都)就公司间接全资附属联邦制药(成都)的股权和该等地块的开发而订立了《投资合作协议》。
根据《投资合作协议》，按照总对价人民币10.3亿元，恒大(成都)已经有条件同意，按人民币8.12亿元对价，以增资入股方式认购联邦制药(成都)约67.0%股权；及联邦制药(香港)已经有条件同意转让、而恒大(成都)亦有条件同意取得联邦制药(成都)余下约33.0%的股权，对价是总对价的余额。联邦制药(成都)目前持有该等用作开发商业住宅物业的地块的权益。
联邦制药(成都)是一家于中国成立的有限公司，于公告刊发的日由公司间接全资拥有。联邦制药(成都)主要从事投资控股业务，并持有该等地块的权益。该等地块为两幅位于中国四川省成都市彭州市牡丹大道南段8号的土地，总地盘面积约324,084.985平方米，不包括其中由联邦制药(成都)向彭州市政府提供用于建设一间行政中心的约40亩的地块，原本用作集团运营生产厂房，后于2014年因生产厂房停业，且与内蒙古的生产业务合并，遂改为商用住宅开发用途。
董事会认为，该项交易正好为集团提供合适机会，变现集团于联邦制药(成都)所持该等地块之投资。此外，该项交易的所得款项将可提升公司的现金流水平，为集团提供额外资金，可以发展集团现有业务并把握其他商机。
预计集团将可从该项交易录得未经审核盈利约人民币3600万元，集团自该项交易收取的所得款项净额，将用于其药品生产及销售业务及一般营运资金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
